The process of identifying and bringing to market novel therapies is extremely challenging and notoriously expensive as most drug candidates fail. In the respiratory area, like in other areas, improving the success rate of new therapeutic entities is one of the industry’s greatest challenges. To do so, the use of reliable methodologies providing sensitive, reproducible, and detailed outcomes predictive of clinical success is key in guiding the strategic decision-making process.
The flexiVent has proven to be an invaluable tool in early drug development. Over the years, it has become the industry standard in terms of preclinical lung function measurements, as evidenced by an ever growing number of related scientific publications and patents. The flexiVent’s exhaustive set of highly reproducible measurements offers outcomes that can be trusted at any point during the preclinical drug development process. The detailed measurements help gather deep insights into respiratory mechanisms early on in the process, preventing additional development costs.
The administration of drugs or novel therapeutic carriers through the lung could be desirable for many reasons. The large surface area and high vascularization of the lung can provide a fast and effective delivery of substances either locally or systemically, via the blood. When considering inhalation as the route for drug delivery, SCIREQ’s intervention platform, the inExpose, offers a significant positive impact on study reproducibility and research efficiency by ensuring process standardization. Integrated with the Aeroneb nebulizer, the inExpose provides sophisticated computer control which enables automated, precise, and repeatable aerosol exposure sessions to small laboratory animals. Furthermore, the inExpose offers small internal volumes, reducing exposure ramp-up times and minimizing the need for large quantities of material.
Respiratory function can be assessed by a number of techniques. Measurements in conscious subjects can be done using various plethysmography techniques such as unrestrained whole body plethysmography (WBP), double chamber plethysmography (DCP), or head-out plethysmography (HOP). While these measurement methods offer the benefit of having the subjects closer to their natural state, uninfluenced by anaesthetic side effects, the trade-off is a lower measurement accuracy and precision.
A comprehensive overview of the pharmacological properties of novel therapies is required to best identify the candidates to move forward in the drug development process. This can be achieved through a range of techniques which includes the classical isolated tissue bath, where external influences can be removed.
Dr. Venkatachalem’s lab focuses on lung diseases such as asthma, chronic obstructive pulmonary disease, LAM, & pulmonary hypertension. This group is leading the research on elucidating the role of sex steroids in lung diseases like asthma.
Still researching your asthma animal model? Learn more about which animal is the most popular asthma animal model, the advantages and disadvantages of each, what goes into a successful model, the sensitization and challenge phases, and much more.
The Halayko lab focuses on the
pathogenesis of bronchial asthma and is at the forefront of preclinical asthma research. We sat down with Dr. Halayko to learn more about his work and get his thoughts on the current state and future of asthma research.
Save time evaluating SCIREQ equipment by having a SCIREQ Application Specialist conduct a custom
literature research. Researchers will receive an email report showing SCIREQ publications relevant to their specific application research area, along with custom equipment recommendations and commentary.
Please fill out the below form and a specialist will contact you as soon as possible